跳到正文
原文
Nature 健康护理主题·· 24 天前精选AI 评分63

分次给药吉妥珠单抗奥唑米星在分子定义的有利风险急性髓系白血病中的疗效

Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia

AI 导读

研究团队通过回顾性分析,发现分次给药的吉妥珠单抗奥唑米星在特定亚组急性髓系白血病患者中有效,且未增加毒性。在有利风险和 NPM1 突变亚组中,分次给药的吉妥珠单抗奥唑米星显著改善无事件生存期和总生存期。

推荐理由

研究团队通过回顾性分析,发现分次给药的吉妥珠单抗奥唑米星在特定亚组急性髓系白血病患者中有效,且未增加毒性。

正文

To the editor,

Randomized trials of gemtuzumab ozogamicin (GO), a CD33 directed antibody-drug conjugate, in combination with conventional anthracycline- and cytarabine-based induction chemotherapy (IC) for acute myeloid leukemia (AML) have shown heterogeneous benefit [1]. High single-dose regimens such as that used in SWOG S0106 showed excess early death and no benefit, whereas fractionated dosing in ALFA-0701 improved event-free survival (EFS) without excess mortality [2,3,4]. A pivotal patient-level meta-analysis of five randomized trials established a clear survival benefit in patients with favorable-risk cytogenetics, with a 20% absolute overall survival (OS) improvement at 6 years, and a smaller intermediate-risk benefit, ~5% at 6 years, with no benefit in adverse-risk disease [5, 6]. However, these analyses relied on cytogenetics alone and predate the molecular risk stratification of the 2022 European LeukemiaNet (ELN), which reclassifies a substantial proportion of patients relative to earlier schemes [7,8,9]. The randomized evidence is strongest in core binding factor (CBF) AML, where GO is now widely considered standard of care, whereas its use in the remainder of the ELN 2022 favorable-risk category is less well defined [9]. Similarly, while the NCCN and other guidelines recommend the use of GO in favorable-risk AML, they do not define which subgroups should be included [10].

In particular, the role of GO in patients who have AML with mutated NPM1 (NPM1mut) is variable, and interpretation of prior trials in this subgroup is limited by variable induction backbones and consolidation strategies. The AMLSG 09-09 study, which used a single 3 mg/m2 GO dose with an experimental chemotherapy backbone in NPM1mut AML, did not meet its primary endpoint and reported higher early mortality in the GO arm, yet showed fewer relapses and greater measurable residual disease (MRD) negativity among patients achieving remission [3, 11]. Consequently, modern data using fractionated GO with a standard IC backbone in ELN favorable-risk and NPM1mut disease remain limited. GO also carries a risk of hepatotoxicity and veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), a potentially fatal concern for patients proceeding to allogeneic hematopoietic cell transplantation (allo-HCT), although fractionated dosing has substantially reduced this risk relative to earlier single high-dose regimens [12]. We therefore examined the real-world outcomes of fractionated GO during IC at a large tertiary referral center, focusing on ELN 2022 favorable-risk (ELN-fav) and NPM1mut AML.

We retrospectively identified sequential patients with newly diagnosed AML receiving IC at a single institution from 2016 to 2023. Patients receiving non-intensive upfront therapy or with incomplete molecular data were excluded, and all underwent comprehensive cytogenetic analysis and next-generation sequencing. The “GO-era” (February 2021 to December 2023) was defined as the period during which GO was available for physician-directed use in combination with conventional IC (daunorubicin 60mg/m2 days 1-3 and cytarabine 100mg/m2 CIVI days 1-7) for patients with favorable, intermediate, or unknown cytogenetic risk in combination with IC. GO was given at 3 mg/m2 on days 1, 4, and 7 of induction. Because it was standard practice to start GO before cytogenetic or molecular results returned, GO was discontinued if FLT3 mutations or adverse-risk cytogenetics were identified, and FLT3-ITD/TKD-positive patients received a FLT3 inhibitor in place of GO. Clinical endpoints, including relapse-free survival (RFS), OS, complete remission (CR), and induction mortality, were defined as per the ELN 2022 criteria. Non-relapse mortality (NRM) was defined as death after allo-HCT for any cause in the absence of disease progression or relapse. Hepatotoxicity was graded by CTCAE v5, and baseline liver impairment was also recorded to contextualize GO-related hepatic effects. RFS and OS were estimated by Kaplan-Meier methods and compared by log-rank tests, with Cox proportional-hazards models used for univariate and multivariable analyses incorporating allo-HCT as a time-dependent covariate. Post-transplant analyses were landmarked at the date of allo-HCT and restricted to transplanted patients, with transplant as time zero. NRM and relapse were analyzed as competing risks (Gray’s test), and analyses were performed in R v4.5.2. The study was approved by the University of British Columbia Research Ethics Board (H25-01553) and conducted in accordance with the Declaration of Helsinki and all applicable guidelines and regulations.

We identified 496 patients (150 ELN-fav, 146 intermediate [ELN-int], 200 adverse [ELN-adv]; mean age 59 years), of whom 114 (23%) received GO (Supplementary Table 1). GO recipients were younger (mean 53 vs 60 years; p < 0.001) and had a more favorable risk profile: ELN-fav disease was more common (43 vs 26%; p < 0.001), adverse disease less common (29 vs 44%; p = 0.003), and TP53 mutations were rare (0.9 vs 8.1%; p = 0.006). Within the GO-era, 76.6% (49/64) of ELN-fav patients received at least one GO dose compared to 52.5% (114/217) overall in the GO-era. Among ELN-fav patients censored at transplant, GO was associated with significantly improved RFS (median not reached vs 18.4 months; p = 0.012; Fig. 1A) and OS (p = 0.048; Fig. 1B). In ELN-int patients, neither RFS nor OS were significantly prolonged (Supplementary Fig. 1A–D). Because FLT3-ITD affects transplant allocation, we evaluated ELN favorable- and intermediate-risk FLT3 wild-type disease, where GO showed a trend toward improved RFS censored at transplant (p = 0.058; Fig. 1C); 24-month RFS was 64.9% with GO versus 38.9% without in this population. In multivariate Cox models for the full cohort, ELN non-favorable risk remained strongly associated with inferior RFS (hazard ratio [HR] 2.25, 95% CI 1.66–3.07, p < 0.001), while any GO was independently associated with improved RFS (HR 0.61, 95% CI 0.44-0.83, p = 0.002) and OS (HR 0.60, 95% CI 0.42–0.87, p = 0.006), with allo-HCT strongly favorable in both models (Table 1 and Supplementary Table 2). An era-based analysis showed ELN-fav RFS improved significantly in the GO-era (median 16.4 months to not reached; p = 0.032), with no significant era differences in ELN-int or ELN-adv groups (Supplementary Fig. 2A–F). Similar results were seen without censoring at allo-HCT (Supplementary Fig. 3A–D).

Fig. 1: Efficacy of gemtuzumab ozogamicin (GO) in ELN 2022 defined molecular subgroups.

A ELN-favorable RFS ± GO (censored at transplant). B ELN-favorable OS ± GO (censored at transplant). C ELN favorable/intermediate FLT3 wild-type RFS ± GO (censored at transplant). D NPM1-mutated RFS ± GO (not censored at transplant). E NPM1-mutated RFS ± GO (censored at transplant). F NPM1-mutated OS ± GO (not censored at transplant).

Table 1 Relapse-free survival in univariable and multivariable Cox regression models.

Full size table

Of 172 patients with NPM1mut, 44 received at least one GO dose and 25 received three induction doses (Supplementary Table 3). GO was associated with significantly prolonged RFS (24-month RFS 57.9 vs 36.0%; p = 0.031; Fig. 1D), which remained significant when censored at transplant (Fig. 1E). In univariate analysis, the effect was strongest with three induction doses (HR 0.37, 95% CI 0.17–0.79, p = 0.010) versus any GO (HR 0.57, 95% CI 0.34–0.96, p = 0.033). In multivariable models with allo-HCT as a time-dependent covariate, three-dose GO remained independently associated with improved RFS (HR 0.37, 95% CI 0.17–0.81, p = 0.013) (Table 1). OS was numerically higher with GO (24-month OS 72.6 vs 58.5%; p = 0.091; Fig. 1F) but not significant in multivariable analysis (Supplementary Table 4).

To address concerns that GO might compromise post-transplant safety, we evaluated post-transplant outcomes among the 281 transplanted patients in the cohort (61 GO-treated). NRM did not differ by GO exposure (24-month NRM 10 vs 12%; Gray’s p = 0.65; Supplementary Fig. 4A), with no significant differences across ELN risk groups (Supplementary Fig. 5A–D). The cumulative incidence of post-transplant relapse was likewise similar (Supplementary Figs. 4B and 6A–D). Landmark post-transplant OS did not differ (24-month OS 73.4% with GO vs 66.9% without GO; p = 0.96 overall log-rank test) or based on ELN risk (Supplementary Fig. 7A–E). Because of an imbalance in TP53 mutations between the GO and no-GO groups, a sensitivity analysis excluding ELN-adv with TP53 mutations was completed, which did not alter any post-transplant findings.

Hepatotoxicity outcomes were reassuring. Baseline liver impairment was more common in the no-GO group (53.1 vs 36.8%; p = 0.002). Rates of any-grade hepatotoxicity during induction were similar with or without GO (70.2 vs 75.4%), as was grade 1–2 hepatotoxicity (58.9 vs 59.6%; p = 0.92) and grade 3–4 hepatotoxicity rates (10.5 vs 16.5%; p = 0.11). When stratified by history of baseline liver disease, hepatotoxicity was driven by prior liver disease rather than GO use and remained similar with and without GO as the severity of prior liver disease increased (Supplementary Table 5). VOD/SOS occurred during induction in three patients (one GO, single dose). Post-transplant VOD/SOS occurred in 6/61 (9.8%) GO-exposed versus 8/220 (3.6%) non-GO patients (p = 0.087); of the six GO cases, four received a single dose, and three had pre-existing liver disease.

In this contemporary real-world cohort, fractionated GO was associated with improved RFS in ELN 2022 favorable-risk and NPM1mut AML, without increased hepatotoxicity or post-transplant NRM. These findings are consistent with the established benefit of GO in high-CD33-expressing favorable-risk disease, potentially improving rates of cure without transplantation. Reduced relapse in this population is likely mediated by reductions in measurable residual disease (MRD); this is a key limitation of our study given the absence of MRD data in our cohort [3, 13, 14]. Although improved RFS was consistently seen, this did not consistently translate to OS, especially in the NPM1mut AML population, which is expected in a cohort with access to effective salvage therapies and transplant. A comparable pattern was observed in AMLSG 09-09, where GO reduced relapse and improved MRD negativity without a survival gain [3]. However, RFS remains a clinically meaningful endpoint given the cost and quality-of-life burden of transplant in second remission [15]. The absence of excess hepatic or post-transplant toxicity, even when GO was administered pending molecular results, supports the safety of early fractionated exposure in patients with minimal hepatic comorbidities [16]. The principal limitations of our study are the retrospective single-institution design, evolving ELN stratification and transplant practices during the study period, and lack of MRD data [7, 17]. Further studies should define the optimal GO dose and its impact on MRD, as well as its role alongside menin inhibitors in NPM1mut AML.

Data availability

Due to privacy regulations, data cannot be shared publicly. Upon request, the corresponding author will consider data requests with the establishment of appropriate data transfer agreements.

References

  1. Boissel N. Where do immunotherapies stand in management of acute leukemia in adults?. Hematology Am Soc Hematol Educ Program. 2025;2025:342–52.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn MWM, Schroeder T, et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10:e495–e509.

    Article  PubMed  Google Scholar 

  4. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–16.

    Article  CAS  PubMed  Google Scholar 

  5. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.

    Article  CAS  PubMed  Google Scholar 

  7. Dohner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

    Article  PubMed  Google Scholar 

  8. Chornenki N, Fadul A, Supan A, Abou Mourad Y, Cherniawsky H, Chung S, et al. Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changes. Blood Neoplasia. 2026;3:100198.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yuan R, Mariano M, Cachia D, Badar T, Patel SA Modern concepts in precision targeting of acute myeloid leukemia based on principles of molecular oncology. Cancers. 2026;18:2329.

  10. Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, et al. NCCN Guidelines® Insights: acute myeloid leukemia, version 3.2026. J Natl Compr Canc Netw. 2026;24:222–9.

    Article  PubMed  Google Scholar 

  11. Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Kronke J, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020;136:3041–50.

    Article  CAS  PubMed  Google Scholar 

  12. Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016;44:61–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute Leukemia French Association Group. J Clin Oncol. 2017;35:185–93.

    Article  CAS  PubMed  Google Scholar 

  14. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.

    Article  CAS  PubMed  Google Scholar 

  15. Alhajahjeh A, Patel KK, Podoltsev NA, Kewan T, Stempel JM, Mendez L, et al. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Adv. 2025;9:5234–46.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ho VT, Martin AS, Perez WS, Steinert P, Zhang MJ, Chirnomas D, et al. Prior gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2020;26:884–92.

    Article  CAS  PubMed  Google Scholar 

  17. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Leukemia/BMT Program data coordinator team for their assistance.

Funding

This study was performed without funding support.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Nicholas Chornenki, Anita Liu, Yasser Abou Mourad, Reyna Altook, Hannah Cherniawsky, Shanee Chung, Donna Forrest, Deepesh Lad, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas Nevill, Judith Rodrigo, Claudie Roy, Kevin Song, Cynthia Toze, Jennifer White, Eric Zhao, David Sanford & Ryan J. Stubbins

  2. Leukemia/BMT Program of BC, BC Cancer and Vancouver Coastal Health, Vancouver, BC, Canada

    Yasser Abou Mourad, Reyna Altook, Hannah Cherniawsky, Shanee Chung, Donna Forrest, Deepesh Lad, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas Nevill, Judith Rodrigo, Claudie Roy, Kevin Song, Cynthia Toze, Jennifer White, Eric Zhao, David Sanford & Ryan J. Stubbins

Authors

  1. Nicholas Chornenki
  2. Anita Liu
  3. Yasser Abou Mourad
  4. Reyna Altook
  5. Hannah Cherniawsky
  6. Shanee Chung
  7. Donna Forrest
  8. Deepesh Lad
  9. Florian Kuchenbauer
  10. Stephen H. Nantel
  11. Sujaatha Narayanan
  12. Thomas Nevill
  13. Judith Rodrigo
  14. Claudie Roy
  15. Kevin Song
  16. Cynthia Toze
  17. Jennifer White
  18. Eric Zhao
  19. David Sanford
  20. Ryan J. Stubbins

Contributions

NC and RJS were responsible for conception, data collection, data analysis, and manuscript drafting. AL was responsible for data collection. YAM, RA, HC, SC, DF, DL, FK, SHN, SN, TN, JR, CR, KS, CT, JW, EZ, and DS were responsible for contributing patients to the cohort. All authors reviewed and approved the manuscript.

Corresponding author

Correspondence to Ryan J. Stubbins.

Ethics declarations

Competing interests

RJS reports honoraria from AbbVie, Astellas, Novartis, Sobi, and Taiho; advisory board from AbbVie, Astellas, BMS, and Kite/Gilead.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chornenki, N., Liu, A., Abou Mourad, Y. et al. Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia. Blood Cancer J. 16, 190 (2026). https://doi.org/10.1038/s41408-026-01655-z

Download citation

  • Received: 23 June 2026

  • Revised: 15 September 2026

  • Accepted: 08 October 2026

  • Published: 27 October 2026

  • Version of record: 27 October 2026

  • DOI: https://doi.org/10.1038/s41408-026-01655-z

来源:Nature 健康护理主题 · nature.com